84 related articles for article (PubMed ID: 3929828)
1. The bioavailability of a slow-release verapamil formulation.
Norris RJ; Muirhead DC; Christie RB; Devane JG; Bottini PB
Br J Clin Pract Suppl; 1985 Jun; 42():9-16. PubMed ID: 3929828
[No Abstract] [Full Text] [Related]
2. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
[TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of two slow-release formulations of verapamil].
Keller-Stanislawski B; Rietbrock N
Arzneimittelforschung; 1990 Oct; 40(10):1086-8. PubMed ID: 2291745
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of once-daily verapamil: comparative bioavailability of two sustained-release formulations.
Muirhead DC; Norris RJ; Cockayne D; Hill GW
Br J Clin Pract Suppl; 1988 Apr; 60():14-9. PubMed ID: 3151264
[No Abstract] [Full Text] [Related]
5. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
Karim A; Piergies A
Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
[TBL] [Abstract][Full Text] [Related]
7. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
[TBL] [Abstract][Full Text] [Related]
8. [Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride].
Guo JL; Jing GW; Cao DS; Li YQ; He HY; Ling LX; Li Z
Yao Xue Xue Bao; 1993; 28(9):714-20. PubMed ID: 8010021
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of a slow-release formulation of verapamil.
Taylor SH
Br J Clin Pract Suppl; 1985 Jun; 42():34. PubMed ID: 3929826
[No Abstract] [Full Text] [Related]
10. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
Marvola M; Kannikoski A; Taskinen J; Ottoila P
J Pharm Pharmacol; 1985 Nov; 37(11):766-70. PubMed ID: 2867156
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
[TBL] [Abstract][Full Text] [Related]
12. Securon SR: sustained-release verapamil.
Drug Ther Bull; 1987 Jun; 25(12):47-8. PubMed ID: 3608822
[No Abstract] [Full Text] [Related]
13. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
[TBL] [Abstract][Full Text] [Related]
14. In vivo performance of controlled release pellets of diltiazem HCl.
Nisarur-ur-Rahman ; K H Y; Jia Woei W
Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
[TBL] [Abstract][Full Text] [Related]
15. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
Retzow A; Schürer M; Schulz HU
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the efficacy of verapamil in slow-release preparations in the treatment of stable exertion angina].
Scrutinio D; Lagioia R; De Toma L; Mangini S; Accettura D; De Nicolò M
Cardiologia; 1982 Oct; 27(10):963-71. PubMed ID: 6927458
[No Abstract] [Full Text] [Related]
17. Serum concentration and antihypertensive effect of slow-release verapamil.
Schütz E; Ha HR; Bühler FR; Follath F
J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man.
Alvisi V; Gasparetto A; Dentale A; Heras H; Felletti-Spadazzi A; D'Ambrosi A
Drugs Exp Clin Res; 1996; 22(1):29-33. PubMed ID: 8839635
[TBL] [Abstract][Full Text] [Related]
19. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium.
Buckley N; Dawson AH; Howarth D; Whyte IM
Med J Aust; 1993 Feb; 158(3):202-4. PubMed ID: 8450791
[TBL] [Abstract][Full Text] [Related]
20. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB
Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
